Biological material collection to advance translational research and treatment of children with CNS tumors: A position paper and practical considerations from the SIOP-Europe Brain Tumor Group by Jones, C
                             Elsevier Editorial System(tm) for The Lancet 
Oncology 
                                  Manuscript Draft 
 
 
Manuscript Number: THELANCETONCOLOGY-D-18-00435R2 
 
Title: Biological material collection to advance translational research 
and treatment of children with CNS tumors: A position paper and practical 
considerations from the SIOP-Europe Brain Tumor Group  
 
Article Type: Policy Review (Unsolicited) 
 
Keywords: CNS tumor, child, tumor tissue, biomaterial, tumor banking 
 
Corresponding Author: Professor Stefan Rutkowski,  
 
Corresponding Author's Institution: University Medical Center Hamburg-
Eppendorf 
 
First Author: Stefan Rutkowski, MD 
 
Order of Authors: Stefan Rutkowski, MD; Piergiorgio Modena, PhD; Daniel 
Williamson, PhD; Kornelius Kerl, MD; Karsten Nysom, MD; Barry Pizer, PhD; 
Ute Bartels, MD; Stephanie Puget, PhD; Francois Doz, MD; Antony 
Michalski, PhD; Katja von Hoff, MD; Mathilde Chevignard, MD; Shivaram 
Avula, FRCR; Matthew  J Murray, PhD; Stefan Schönberger, MD; Thomas 
Czech, MD; Antoinette Y N Schouten-van Meeteren, MD; Uwe Kordes, MD; 
Christof M Kramm, MD; Dannis G van Vuurden, MD; Esther Hulleman , PhD; 
Geert O Janssens, MD; Guirish A Solanki, FRCS; Marie-Luise C van Veelen, 
MD; Ulrich Thomale, MD; Martin U Schuhmann, MD; Chris Jones, PhD; Steve C 
Clifford, PhD; Stefan M Pfister, MD; Stefaan W van Gool, MD 
 
Manuscript Region of Origin: GERMANY 
 
Abstract: Pediatric central nervous system (CNS) tumors are the most 
common cause of childhood cancer-related morbidity and mortality. 
Improvements in diagnosis and treatment are mandatory. New (epi)genetic 
information is transforming the field dramatically. For most pediatric 
CNS tumor entities, subgroups with distinct biological characteristics 
are identified and increasingly used for accurate diagnoses and 
therapeutic recommendations.  
Future treatments will be further tailored to specific molecular subtypes 
of disease, specific tumor predisposition syndromes, and other biological 
criteria. Currently, deficits in structures and interdisciplinary 
cooperation are impeding the collection of high-quality biomaterial in 
most centers. However, successful material collection is a key 
prerequisite for the application of contemporary methodologies for 
validation of candidate prognostic factors, the discovery of new 
biomarkers, the establishment of appropriate pre-clinical research models 
for targeted agents, the faster clinical implementation of precision 
medicine, and for other therapeutic use of the tissue, e.g. for 
immunotherapies. Practical, legal and ethical aspects of consent, 
storage, material transfer, biobanking, data sharing, and funding must be 
established by research consortia and local institutions for optimal 
collection of primary and subsequent tumor tissue, body fluids, and 
normal tissue. These requirements must be adapted to the individual 
personal and organizational structures of the local institutions.  
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Abstract 
 
Pediatric central nervous system (CNS) tumors are the most common cause of childhood cancer-
related morbidity and mortality. Improvements in diagnosis and treatment are mandatory. New 
(epi)genetic information is transforming the field dramatically. For most pediatric CNS tumor entities, 
subgroups with distinct biological characteristics are identified and increasingly used for accurate 
diagnoses and therapeutic recommendations.  
Future treatments will be further tailored to specific molecular subtypes of disease, specific tumor 
predisposition syndromes, and other biological criteria. Currently, deficits in structures and 
interdisciplinary cooperation are impeding the collection of high-quality biomaterial in most centers. 
However, successful material collection is a key prerequisite for the application of contemporary 
methodologies for validation of candidate prognostic factors, the discovery of new biomarkers, the 
establishment of appropriate pre-clinical research models for targeted agents, the faster clinical 
implementation of precision medicine, and for other therapeutic use of the tissue, e.g. for 
immunotherapies. Practical, legal and ethical aspects of consent, storage, material transfer, 
biobanking, data sharing, and funding must be established by research consortia and local 
institutions for optimal collection of primary and subsequent tumor tissue, body fluids, and normal 
tissue. These requirements must be adapted to the individual personal and organizational structures 
of the local institutions.  
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Introduction 
 
In developed countries, cancer is the leading disease-related cause of death in childhood. Pediatric 
central nervous system (CNS) tumors are the most common group of solid pediatric malignancies and 
the most common cause of cancer-related morbidity and mortality in this age group. Incidence rates 
between 5.37 and 4.01 per 100.000/year have been reported for children between 0 and 15 years 1,2. 
Pediatric CNS tumors comprise a group of highly heterogeneous entities with strikingly different 
clinical and biological characteristics compared to adult CNS tumors 3. In spite of significant advances 
in imaging, neurosurgery, radiotherapy, and medical treatment, survival rates for most pediatric CNS 
tumor patients are lagging behind the success rates of childhood leukemia and many other solid 
tumor types 4-6. In addition, survivors of childhood CNS tumors most often suffer impaired quality of 
life, including frequent and disabling endocrine and neuro-cognitive impairments which not only 
negatively impact their physical and mental health but also their participation in society. These 
deficits are related to the tumor itself, as well as to surgery and additional CNS-directed therapies, 
that are known to be particularly detrimental when applied on an immature developing brain 7,8. 
Improvements in diagnosis, including shorter time to diagnosis, more accurate of diagnosis and risk 
stratification, and better treatment are urgently needed. The biological knowledge about pediatric 
CNS tumors has been increasing dramatically in the past 5 to 10 years, including newly identified 
subgroups with prognostic and often therapeutic implications. The improved availability of 
biomaterials for biological characterization before the start of postoperative treatment is a 
prerequisite for benefits of individual patients, as well as for the timely clinical validation of current 
knowledge and further scientific progress in the field.  
 
The importance of biological assessments in pediatric CNS tumors 
 
Tumor classification and clinical relevance 
New innovative genomic and epigenetic information is increasingly transforming the diagnostic and 
clinical landscape 9,10. For the large majority of pediatric CNS tumor types, distinct subgroups with 
different epidemiological, clinical, and biological characteristics have been identified, and novel 
subgroups continue to emerge as profiling resolution and cohort sizes increase 11-13. Due to the high 
clinical relevance, the genome-wide analysis of childhood CNS tumors has become increasingly 
important 12.  
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Consequently, some of the most robustly validated new biological parameters, especially in 
medulloblastoma, high grade glioma and ependymoma, have been included into the 2016 version of 
the WHO Classification of Tumors of the Central Nervous System 3.  
For example, in the previous WHO-classification 14, the diagnosis of medulloblastoma and its 
subtypes was defined by histopathological parameters (desmoplasia, anaplasia, or large-cell 
components). In addition to histopathological features the 2016 WHO version defines 
medulloblastoma subgroups by molecular characteristics i.e. WNT-, sonic hedgehog (SHH)-, 
TP53mutated/SHH-, group 3 and group 4 3. The biological understanding and prognostic value of 
other parameters in medulloblastoma continues to emerge as profiling resolution and cohort sizes 
increase. Novel molecular subgroups, predictive of disease risk within Group 3 and Group 4 tumors, 
have recently been reported 11, alongside the discovery of biomarkers defined by specific aberrations 
(e.g. chromosome 11 loss in Group 4 medulloblastoma 15), which now require further validation prior 
to clinical use. Recent analyses of neurocognitive outcomes per biological subgroups in 
medulloblastoma showed that biological subgroups have an association with clinical, neurocognitive 
and health-related quality of life outcomes, with different rates of post-operative complications (less 
cerebellar mutism and motor deficits, less pronounced information processing speed decline, and 
better health-related quality of life in surviving SHH patients) 16,17. It has been agreed internationally 
that whenever possible, patients should be treated on a molecularly informed clinical trial. The first 
international clinical trials of risk-adapted therapies focused on the assessment of clinical, 
pathological and molecular biomarkers are now underway (NCT02066220, NCT01878617), based on 
risk stratification schemes defined in previous trial-based biological research studies, e.g. from Ellison 
et al. 18. Finally, first insights are emerging into the biology of medulloblastoma at relapse; these have 
shown that the disease evolves clonally and that genetic events, such as combined TP53 mutations 
and MYC/N amplification, are commonly acquired at relapse 19,20. Assessment of distinct molecular 
features at relapse will thus be essential for determining the treatment strategy. 
In pediatric high-grade gliomas, the molecularly defined new tumor entity, diffuse midline glioma 
(DMG IV) has been introduced, which is exclusively defined by demonstration of K27M mutations in 
the H3F3A (histone 3.3) or HIST1H3A/B/C (histone 3.1) genes. This tumor entity and its WHO grade 
are defined by demonstration of specific histone mutations besides infiltrative growth characteristics 
and midline location, rather than by the usual histological criteria of malignant tumor growth. Of 
note, H3G34R/V tumors (about 10 to 15%) were not mentioned separately despite clear age, 
location, outcome and biological differences. Furthermore, rare pediatric high grade gliomas (HGG) 
such as WHO grade III anaplastic oligodendroglioma (AO III), WHO grade III anaplastic ganglioglioma 
(AGG III), and WHO grade III anaplastic pleomorphic xanthoastrocytoma (APXA III) are also mostly 
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defined by specific molecular findings or their absence. For pediatric AO III, the usual 1p 19 q co-
deletion which defines most adult AO III according to the new WHO brain tumor classification, is 
mostly absent in their pediatric counterparts. BRAF mutations (as well as homozygous CDKN2A/B 
deletions) may characterize pediatric AGG III and APXA III. The integrated genomic, epigenomic and 
transcriptomic data across anatomical compartments of the brain is needed to define subgroups 
within pediatric high-grade glial tumors (malignant glioma and diffuse intrinsic pontine glioma) as 
well as novel therapeutic targets 21,22. 
For ependymoma, the assessment of RELA-fusion is required for diagnoses according to the 2016 
classification, while posterior fossa biological subgroups A and B (PFA and PFB 23) have not yet been 
introduced into the WHO classification. In addition, further prognostic markers have been confirmed 
retrospectively in multiple case series (1q gain, CDKN2A homozygous deletion, TNC expression, Yap1-
fusion gene) 24. The current consensus on the clinical management of intracranial ependymoma and 
its molecular variants has recently been published, and states that ependymoma is a (molecularly) 
heterogenous disease 25. However, the clinical relevance of many driver epigenetic and genetic 
alterations, either as prognostic markers or as markers predictive of therapeutic efficacy, remains to 
be prospectively validated.  
CNS primitive neuroectodermal tumors (CNS-PNET) were classified as one entity of embryonal brain 
tumors in the previous WHO-classification 14. In the meantime, it has become clear e.g. by DNA 
methylation profiling that a major part of tumors previously classified as CNS-PNETs, can be 
reclassified as other malignant CNS tumors such as high grade glioma, pleomorphic 
xanthoastrocytoma, atypical teratoid/rhabdoid tumor (AT/RT), ependymoma etc. 26. Another major 
subset can be classified as embryonal tumors with multilayered rosettes (ETMR) by LIN28 expression 
analysis and 19q13.42 amplification detection 27. New molecular entities have been described among 
the former group of presumed CNS-PNETs: CNS-neuroblastoma with FOXR2 activation (CNS NB-
FOXR2), CNS high-grade neuroepithelial tumor with MN1 alteration (CNS HGNET-MN-1) or with BCOR 
alteration (CNS-HGNET-BCOR), and CNS Ewing sarcoma family tumor with CIC alteration (CNS EFT-
CIC) 26. 
The majority of molecular profiling performed on atypical teratoid/rhabdoid tumors tissue to date 
points strongly towards the existence of multiple molecular subgroups within the disease 28. It is 
imperative to consolidate these early findings into a consensus molecular classification which may be 
applied to further tumor samples and tested against high-quality clinico-pathological data to validate 
the prognostic nature of any molecular sub-groupings.  
During the past decade the molecular background of pediatric low grade gliomas (LGG) has become 
clear, showing that LGG and glial-neuronal tumors are mainly driven by altered signaling in the RAS-
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MAPK pathway 29. In particular, pilocytic astrocytoma shows mainly BRAF tandem duplications at 
chromosome 7q34 mainly with fusion of KIAA549 and BRAF in 65% leading to loss of the regulatory 
N’-terminal region of BRAF and the formation of fusion proteins. This BRAF fusion correlates with 
improved progression-free survival (PFS) 30. Besides the fusion as biologic background tumorigenic 
BRAF activation occurs in ganglioglioma and pleomorphic xanthoastrocytoma with point mutations at 
position 600 with glutamate substitution for valine, BRAFV600E. Other oncogenetic changes in LGG 
are found in rearrangements of FGFR1, MYB and MYBL1 associated with morphologies of DNET and 
angiocentric glioma respectively 31. The malignant transformation found in about 2% of children with 
LGG has been found to be related to additional homozygous deletion of CDKN2A 32. 
The mutational landscape of CNS germ cell tumors (GCT) is becoming described 33-36 and highlighted 
the biological similarity of these tumors to their extracranial counterparts. These studies have 
identified mutational activation of KIT/RAS/ERK and AKT as well as the PI3K/MTOR pathways, 
representing potential targets for therapy. Given the limited CNS GCT tissue specimens available to 
study in North America and Europe, collection of serum/plasma and CSF may in future allow non-
invasive diagnosis using the elevation of specific microRNAs (miR-371~373 and miR-302/367) 37, 
based on findings in GCT tissues 38. In addition, these less-invasive biospecimens will allow the 
identification of specific mutations through circulating tumor DNA (ctDNA) analysis 39, which may 
inform prognosis and/or novel treatment strategies. 
Recent research revealed the frequent presence of a BRAF mutation in papillary craniopharyngioma 
CP) 40 and first case reports document excellent response rates to BRAF inhibitors in adults 41. 
However, this treatment option – potentially avoiding invasive surgery or radiation and associated 
complications – does not apply to adamantinomatous CP (aCP) in children. Despite limited availability 
of pediatric tissue specimen, promising biological research relating to aCP 42,43 has been published 
with the prospect of identifying targets for new therapies. This research is of fundamental 
importance to children affected by aCP but can only be continued if tumor specimen including cyst 
fluid are routinely sampled. 
In its 2007 and 2016 editions, the WHO classification discerns three grades of choroid plexus tumors 
(CPT): classical plexus papilloma grade I (CPP), atypical plexus papilloma grade III (APP) and plexus 
carcinoma grade III (CPC). Recently several groups have shown that DNA methylation, SNP-profiling, 
and gene expression defines clinically overlapping groups of CPTs 44. 
The accelerated understanding drove the decision for an earlier, 4th edition update of the CNS WHO 
rather than waiting longer for a 5th edition. However, there is still concern that the pace of change in 
the field creates a need to evaluate classification progress faster than is possible through standard 
WHO updates. Therefore, an initiative to evaluate and recommend proposed changes to future CNS 
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tumor classifications has been announced: cIMPACT-NOW, the Consortium to Inform Molecular and 
Practical Approaches to CNS Tumor Taxonomy. The goal of cIMPACT-NOW is to facilitate input and 
consensus review of novel diagnostically relevant data and determine how such information can be 
practically incorporated into future CNS tumor classifications 45. 
 
Access to novel therapies  
 
Importantly, the SIOPe has called for revisions to the EU Pediatric Medicine Regulation, aiming to 
increase young patients’ access to innovative therapies. This call resulted in a specific report from the 
European Commission to the European Parliament and the Council describing “The state of pediatric 
medicines in the EU - 10 years of the EU Pediatric Regulation”, which concluded that the Pediatric 
Use Marketing Authorizations (PUMA) concept has so far failed to incentivize the development of 
pediatric medicines 46. In North America, the RACE (Research to Accelerate Cures and Equity) for 
Children Act would require companies to apply PREA (Pediatric Research Equity Act) to any 
treatment with a molecular target that is relevant in adult and childhood disease. Successful 
biomaterial collection is a key prerequisite for preclinical research projects aiming to identify 
effective new drugs for children with CNS tumors, and therefore will contribute to their improved 
access to novel therapies.  
 
Tumor predisposition genes 
 
In addition to the entity-specific aspects, germline mutations in tumor predisposition genes in 
pediatric cancer are more frequent than previously thought. They have been shown in 8.6 % of 
pediatric brain tumor patients, and some of the pediatric cancers most often associated with 
germline mutations are CPT, atypical teratoid/rhabdoid tumors, medulloblastoma (TP53-mutated 
SHH MB – potential Li-Fraumeni syndrome, PTCH or SUFU-mutated SHH MB – Gorlin syndrome, APC-
mutated WNT MB – Turcot syndrome), HGG, LGG and ependymoma 47. Patients and families need to 
be referred for genetic counseling, to be informed of potential underlying predisposition syndromes. 
 
 
The importance of adequately sampled and stored biomaterial 
 
The main advantages of the collection of biomaterials in adequate quality and quantity are the 
improved etiopathological understanding of pediatric CNS tumors, the validation and discovery of 
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prognostic factors and drugable targets, the improvement of first-line and relapse treatment 
decisions for individual patients as well as within clinical trials and related research, the possibility to 
use the tissue for tumor vaccination strategies, and new insights in biology of acute toxicities and 
late-effects. In addition, frequencies of tumor predisposition syndromes and their clinical behavior 
can only be better understood by analyzing broader series of tumor- and germline material from 
patients with well-annotated clinical information about familiar history, diagnosis, treatment and 
follow-up. In consequence, bio-pathological characterization is now essential for diagnosis, risk 
assessment, therapeutic stratification and potentially specific treatment allocation in all patients with 
medulloblastoma, as well as underpinning future research studies and discoveries. Therefore, 
comprehensive bio-pathological characterization is routinely required before the start of 
postoperative treatment (e.g. radiotherapy, neoadjuvant or adjuvant chemotherapy) in individual 
patients. The most relevant arguments are listed in table 1. 
 
The need for tumor tissue for precision medicine 
 
Broadly applicable methods for the genomic analysis of childhood brain tumors including methods 
for genome-wide discovery and precision medicine have been established 12. However, broader 
availability of tumor- and constitutional DNA is required to understand the full spectrum of 
frequencies and the important clinical implications regarding targeted treatments, treatment-related 
toxicities, secondary malignancies, and the optimal treatment and surveillance strategies for those 
patients and families. In this regard, it will be important to develop appropriate research models for 
each specific pediatric CNS tumor type and subtype to test new treatments and targeted agents. 
Currently, a number of primary cell lines and corresponding orthotopic xenograft models have been 
developed for medulloblastoma 48-51, and HGG/DIPG 52-55, but good orthotopic patient-derived 
xenograft (PDX) models for all other types of CNS tumors are scarce or lacking. Thus, while collecting 
material for tumor characterization, some tissue or CUSA (Cavitron Ultrasonic Surgical Aspirator) 
material should also be collected for the establishment of cell cultures, animal models or organoids 
56.  
Beyond current exploratory and validation research activities, biology data will also be needed for 
future diagnostic re-evaluations. Especially in long duration clinical trials, relevant improvement of 
knowledge on diagnostic groups as well as relevant host factors (cancer predisposition, genotype 
variants in treatment efficacy) can emerge between time of patient inclusion and trial data analysis. 
Also, stored research material helps to characterize rare tumors that do not fall into any of the 
currently appreciated entities.  
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The importance of biological assessments with relevance to tumor imaging 
 
The radiological heterogeneity of individual tumor types is increasingly apparent with advances in 
qualitative and quantitative analysis of both conventional and advanced MR imaging methods 57,58. In 
addition to pathological classification, the emerging evidence of the biological variations, particularly 
molecular subgroups has stimulated interest in the field of imaging genomics or radiogenomics that 
focuses on the relationship between imaging phenotypes and genomics. 
Recent studies have identified correlations between IDH mutation status in gliomas and relative 
cerebral blood volume (rCBV) 59. Detection of 2-hydroxyglutarate (2-HG) on MR spectroscopy has 
been proposed as a useful biomarker for Gliomas with IDH 1 mutation 60. In the pediatric population 
MR characteristics of medulloblastoma subtypes have been described based on conventional imaging 
61 and MR spectroscopy 62. Similar studies need to be carried out in various pediatric brain tumors to 
identify imaging surrogates or biomarkers that complement their biological profile. The collection of 
biological material is central to the development of radio genomics in pediatric neurooncology. It has 
the potential to aid decision making prior to surgery, guiding biopsy and measure efficacy of 
treatment using quantitative methods.  
 
The current situation and shortfalls 
 
Currently, the collection of high-quality, adequately sampled and stored biomaterial is implemented 
successfully only in a minority of centers. This is mainly due to deficits in established structures, 
interdisciplinary cooperation, and funding. Professionally trained staff and required equipment is 
only available in some centers, and may also need to be professionalized at the central level of 
research consortia. Active collaboration of all involved disciplines, including neurosurgeons, 
neuropathologists, and pediatric oncologists, is not always established, and might be compromised 
due to potential conflicts of interest with other local research initiatives. In addition, the required 
personal and infrastructural burden for successful biomaterial collection is not adequately 
compensated by additional funding. 
 
Proposals for improved biomaterial collection 
 
To overcome the current limitations, strong cooperative efforts of representatives from all involved 
disciplines are required. The collection and storage of required biomaterial must become a routine 
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standard for all children with CNS tumors, regardless of their inclusion in clinical trials or other 
research initiatives. Moreover, it must become increasingly mandatory in future prospective 
pediatric CNS tumor trials. For their optimal collection in local institutions and within cooperative 
research groups, clear definitions of the types of biomaterials with standard operating procedures 
(SOP) must be implemented, together with thorough solutions for all associated ethical, legal and 
practical aspects.  
 
Which biomaterials need to be collected and how? 
 
To maximize the above mentioned advantages and to obtain a comprehensive biological 
understanding of tumor and host-related factors, different types of biomaterials need to be 
collected. Adequate amounts of tumor tissue, taking into account safety of the patient, should be 
collected threefold: 1/ as unfixed snap-frozen tissue, 2/ as formalin-fixed paraffin embedded 
material, and 3/ as viable native material in transport media (or viably frozen cells) for direct tumor 
cell culture or direct xenografting in animals. Blood as preferred choice or buccal swabs should be 
collected for germline analyses. In addition, constitutional DNA is required for comparison with 
genomic analyses from the corresponding tumor tissue, as tumor-specific alterations of genes, 
related signaling pathways, and drugable targets can only be identified and understood by 
comparison of tumor and germline material. A list of types of biomaterials to be collected and 
technical aspects of collection and storage is given in Table 2. 
Various technical aspects of collection and storage of biomaterials need to be carefully considered to 
obtain useful amounts of the required materials of optimal quality. This requires first of all a 
fundamental change in the pediatric neurosurgeons perception, that they play two equally important 
and pivotal roles in the process of treatment. Neurosurgeons need to appreciate, that apart from 
their primary role with regard to performing ideally a gross total tumor resection without causing any 
additional harm to the patients, there is an equally important secondary role by performing a 
threefold tissue sampling during surgery. 
The operative procedure per se should be adapted, because much more time needs to be devoted to 
collect tissue with tumor grasping forceps from different areas of the tumor, instead of mostly using 
suction or ultrasonic aspirators to take out the bulk of tumor tissue. Piecemeal sampling with the 
tumor forceps is, especially in either very soft or very hard-elastic tumors, very time- and patience 
consuming and can prolong a surgical procedure up to 30 minutes, especially if tumors are very 
bloody. Information about the heterogeneity of tumors from MRI (diffusion-weighted sequences) or 
positron-emission-tomography may be used to specifically obtain tissue from various tumor areas. 
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In addition, a more or less self-running tissue processing SOP needs to be enacted among the theater 
staff, because the sampled tissue needs to be processed in parallel to the tumor removal, which 
takes full attention of the surgeon and the scrub nurse. The pathologist might be involved at that 
time to determine the samples collected being tumor tissue. After the end of the collection period, 
samples need to be transferred by a third person from the staff to sterile vials and immediately snap 
frozen in -80ºC freezers or liquid nitrogen, either option needs to be available close to the operating 
rooms. The samples for tissue cultures need to go into appropriate vials with media for delayed 
transfer to the lab within 24h or have to be transferred directly to the lab. Only the usual pathology 
for FFPE material can stay and be processed „as always“. However, neurosurgeons need to know that 
molecular genetic array diagnostics need additional material to extract enough DNA. Thus, generous 
sampling is essential and the time needs to be invested.  
To make the tissue sampling SOP work well, theater staff needs to be informed and made 
enthusiastic for this additional work they have to cope with. There needs to be a thorough 
understanding in all personnel involved, that the tissue processing they are performing is not “just 
for research”, but has an enormous impact on the patients chances of survival, equal to the impact of 
operation and tumor removal itself. Understanding the importance of their role in this process will 
make them efficient and reliable members of the process.  
Finally the sampling effort is a team effort and, despite the fact that it is done in the neurosurgical 
theater, the neurosurgeon’s focus will properly be on the operation itself. Thus the tissue processing 
pipeline needs to be established as an interdisciplinary effort and adapted to the local conditions 
including oncology, pathology and theater staff. Since especially malignant tumors of the posterior 
fossa might undergo emergency surgery or weekend surgery, the SOP for tissue processing needs to 
be organized in a way that it will function 24/7. 
Blood, plasma and serum are important to elucidate the role of circulating tumor cells, extracellular 
vesicles, cell-free DNA, proteins and other key parameters. Cerebrospinal fluid samples can be used 
in metastatic tumors, as the access to macroscopic metastatic lesions is frequently limited and only 
possible by additional invasive procedures. Appropriate diagnostic methods for liquid biopsy may 
serve to identify future markers for minimal residual disease 63,64. As tumor tissue from metastatic 
sites can otherwise only be obtained by more invasive procedures, cerebrospinal fluid (CSF) may not 
only be used to detect microscopic tumor dissemination in cytospin samples, but may also serve to 
analyze metastatic tumor DNA, microRNA (miRNA) or proteins in the CSF-supernatant, to enhance 
knowledge about metastatic tumor spread or disease progression/evolution. 
Importantly, biologic material should also be collected later-on during the disease course and after 
treatment. To speed up the biological understanding of tumor evolution and the appearance of 
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resistance mechanisms, it is of paramount importance to collect tumor tissue at the time of relapse, 
or through autopsy. To ensure maximal biological information at tumor recurrence, re-biopsy of 
relapsed tumors should be generally recommended, with exceptions only if associated risks are 
increased in individual cases.  
In addition to the specifications about the collected biomaterial outlined above, there are important 
considerations at the ‘central’ level of research consortia or clinical trial groups, as well as at the level 
of ‘local’ institutions (figure 1). Moreover, ethical, legal and practical aspects must be considered.  
 
Ethical, legal, privacy, and practical aspects at the central level of a research consortium or clinical 
trials group 
 
Studies have shown clear support from patients and their representatives, who, once in receipt of 
adequate information, are largely in favor that biomaterials not required for diagnostic procedures 
are made available for research projects 65,66. However, important ethical, legal, privacy and practical 
aspects need to be considered in the process of collection, storage, shipment, and sharing of 
biomaterials. For example, the legal definitions for ownership of biomaterials, and guidelines for 
informed consent may vary between countries 67, and need to be considered for individual patient 
care and in the conduct of international clinical trials. Due to the advantages of accurate diagnostic 
procedures and translational research, it is increasingly accepted that the availability of biomaterials 
is defined as a mandatory inclusion criterion for patients within clinical trials (e.g. within the SIOPE-
PNET5-MB trial 68). This may not only be justified if biomaterial is a prerequisite for stratification of 
patients within a clinical trial, but also to ensure maximal scientific progress from associated 
biological research projects. The availability of biomaterials will facilitate future diagnostic and 
research evaluations of newly defined biomarkers, targets or host factors, which may impact on the 
understanding of the clinical results of the trials. The main ethical, legal, privacy, and practical 
aspects of storage, sharing, and shipment of biomaterials are listed in Table 3. 
 
Biobanking 
 
In addition, advantages of central or decentralized (virtual) biobanking need to be considered. 
Biomaterials can be stored centrally by academic or commercial tumor bank providers, with software 
systems allowing for maximal transparency about the stored materials. Alternatively, they can be 
stored within the respective local tumor banking facilities, and may be shipped according to the 
requirements of further analyses (diagnostic analyses or collaborative research projects) in batches 
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at later time points. Both central and decentral storage of biomaterials will also allow its use for big 
data analyses with bioinformatical support, and facilitate a comprehensive cataloguing of 
biomaterials for collaborative projects between research consortia. In any case, SOPs to control 
tumor samples for appropriate tissue representation must also be implemented. Storage of 
biomaterials in aliquots allows the tissue to be used for multiple research projects. Transparent 
criteria for the access of scientists from local contributing institutions and for independent 
researchers to the larger biomaterial series may positively impact the cooperation of local centers. 
Material transfer agreements, SOPs for shipment of materials, and adequate coverage of costs may 
further facilitate cooperative tumor-banking. In addition, it is important to define coupling of tumor 
material data to patient data: genomic, transcriptomic, methylomic, metabolomics data from tumor 
biopsies, as well as data from experiments on patient-derived cell cultures and xenografts, should 
ideally be stored in an international CNS tumor registry such as the recently established SIOPE DIPG 
Registry 69, together with comprehensive anonymous clinical, radiological and pathology data of 
these patients. This will allow for comprehensive Big Data analyses. In this respect, it is of high value 
to invest in gathering large numbers of retrospective clinical data (baseline characteristics, treatment 
and survival data) from multiple international groups, and to correlate these with analysis of 
(epi)genomic data from corresponding banked tumor samples.  
National and international research consortia and/or clinical trial groups must consider these aspects 
and discuss these early in the planning phase of collaborative projects, so that specific national 
requirements can be implemented in timely manner. Sustainability of data beyond projects and 
connection of data at overarching levels should be envisioned. Recent large-scale sequencing by 
International Cancer Genome Consortium and Paediatric Cancer Genome Project has further shown 
that the genetic and epigenetic repertoire of driver mutations in specific childhood malignancies 
differs from more common adult-type malignancies. To bring about much needed change, pediatric 
platforms such as ACCELERATE have been proposed by the Cancer Drug Development Forum, 
Innovative Therapies for Children with Cancer, the European Network for Cancer Research in 
Children and Adolescents and the SIOPe 70. These platforms aim to develop mechanism-of-action 
informed paediatric drug development programmes with aggregated databases of paediatric 
biological tumour drug targets, to ultimately enable prioritisation and conduct of early phase clinical 
paediatric trials more rapidly. 
 
 
Local institutions need to implement practical solutions according to their structures 
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It has become evident that the collection and storage of biomaterials can only be achieved 
successfully, if all relevant steps are solved in each local participating center. As personal and 
organizational structures are highly different between local participating centers, a general schema 
may not work in all centers in the same way. The above mentioned aspects rather need to be 
adapted individually by the local institutions to their structures, ideally by a dedicated local 
coordinator supported by all other involved disciplines (see table 4). Ultimately, the practical tasks 
and responsibilities need to be defined and assigned to responsible individuals. Specific education 
and training modules should be developed. 
 
Conclusion 
 
The availability of adequately sampled and stored biomaterial will confer multiple advantages of 
highest scientific and clinical relevance, such as validation of described and identification of new 
prognostic factors and drugable targets. This paper aims to stress on the need of biomaterial 
sampling, and includes also highly relevant practical, ethical, and privacy aspects. Improved sampling 
of biomaterial is a major prerequisite for the improvement of survival rates for children with CNS 
tumors, and to reduce treatment-related late-effects.  
In addition to increasing knowledge about the roles of conventional treatment modalities in 
biologically well-defined entities and subgroups, it must be ensured that children are not left behind 
while precision oncology offers new treatment solutions for adult cancers 71. As pediatric tumors are 
clinically and biologically highly distinct from adult cancers, these approaches must be redeveloped in 
oncologic diseases, with informative biomaterial. Ideally, data from tumor tissues and biomaterials 
would be coupled to corresponding anonymous patient data, such as demographics, diagnostic 
features, radiology and pathology treatment and outcome data, as exemplified by the recently 
established SIOPE DIPG Registry. 
Only with widely available informative biological material, profound improvements can be achieved 
in reasonable time, both for individual patients as well as for future clinical trial groups of patients. 
Without the proposed improved biomaterial collection, optimal patient care cannot be delivered at 
the level of diagnostic assessments, applied treatment components, and after care. Likewise, the 
urgently required scientific progress in the field will be significantly delayed or impeded. 
 
In summary, tumor tissue and other biomaterials need to be collected from all children with CNS 
tumors, and will become increasingly mandatory in prospective pediatric CNS tumor trials. Strong 
cooperative efforts of representatives from all involved disciplines, in local institutions and within 
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cooperative research groups, are required to efficiently implement the collection and storage of 
required biomaterial.  
 
Search strategy and selection criteria 
 
In this review, chairs and representatives of the SIOPe Brain Tumor Group (BTG) 
(https://www.siope.eu/european-research-and-standards/clinical-research-
council/siopecrc/european-clinical-study-groups/siope-brain-tumour-group/) have summarized their 
views how to efficiently improve biomaterial collection for children with CNS tumours, and why this 
is urgently required. This has been based on the profound experiences in the conduct of national and 
international multicenter clinical trials and collaborative research projects. Cited literature for this 
policy review has been primarily selected by relevance and actuality rather than being object of 
systematic literature review. SIOPe BTG is a European multidisciplinary association of healthcare 
professionals which leads in research, treatment (among which international clinical trials) and care 
of children and young people with tumors of the CNS. It is a subgroup of the European branch 
(SIOPe) (http://www.siope.eu/) of the International Society of Paediatric Oncology (SIOP) 
(http://siop-online.org/).  
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Abstract 
 
Pediatric central nervous system (CNS) tumors are the most common cause of childhood cancer-
related morbidity and mortality. Improvements in diagnosis and treatment are mandatory. New 
(epi)genetic information is transforming the field dramatically. For most pediatric CNS tumor entities, 
subgroups with distinct biological characteristics are identified and increasingly used for accurate 
diagnoses and therapeutic recommendations.  
Future treatments will be further tailored to specific molecular subtypes of disease, specific tumor 
predisposition syndromes, and other biological criteria. Currently, deficits in structures and 
interdisciplinary cooperation are impeding the collection of high-quality biomaterial in most centers. 
However, successful material collection is a key prerequisite for the application of contemporary 
methodologies for validation of candidate prognostic factors, the discovery of new biomarkers, the 
establishment of appropriate pre-clinical research models for targeted agents, the faster clinical 
implementation of precision medicine, and for other therapeutic use of the tissue, e.g. for 
immunotherapies. Practical, legal and ethical aspects of consent, storage, material transfer, 
biobanking, data sharing, and funding must be established by research consortia and local 
institutions for optimal collection of primary and subsequent tumor tissue, body fluids, and normal 
tissue. These requirements must be adapted to the individual personal and organizational structures 
of the local institutions.  
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Introduction 
 
In developed countries, cancer is the leading disease-related cause of death in childhood. Pediatric 
central nervous system (CNS) tumors are the most common group of solid pediatric malignancies and 
the most common cause of cancer-related morbidity and mortality in this age group. Incidence rates 
between 5.37 and 4.01 per 100.000/year have been reported for children between 0 and 15 years 1,2. 
Pediatric CNS tumors comprise a group of highly heterogeneous entities with strikingly different 
clinical and biological characteristics compared to adult CNS tumors 3. In spite of significant advances 
in imaging, neurosurgery, radiotherapy, and medical treatment, survival rates for most pediatric CNS 
tumor patients are lagging behind the success rates of childhood leukemia and many other solid 
tumor types 4-6. In addition, survivors of childhood CNS tumors most often suffer impaired quality of 
life, including frequent and disabling endocrine and neuro-cognitive impairments which not only 
negatively impact their physical and mental health but also their participation in society. These 
deficits are related to the tumor itself, as well as to surgery and additional CNS-directed therapies, 
that are known to be particularly detrimental when applied on an immature developing brain 7,8. 
Improvements in diagnosis, including shorter time to diagnosis, more accurate of diagnosis and risk 
stratification, and better treatment are urgently needed. The biological knowledge about pediatric 
CNS tumors has been increasing dramatically in the past 5 to 10 years, including newly identified 
subgroups with prognostic and often therapeutic implications. The improved availability of 
biomaterials for biological characterization before the start of postoperative treatment is a 
prerequisite for benefits of individual patients, as well as for the timely clinical validation of current 
knowledge and further scientific progress in the field.  
 
The importance of biological assessments in pediatric CNS tumors 
 
Tumor Cclassification and clinical relevance 
New innovative genomic and epigenetic information is increasingly transforming the diagnostic and 
clinical landscape 9,10. For the large majority of pediatric CNS tumor types, distinct subgroups with 
different epidemiological, clinical, and biological characteristics have been identified, and novel 
subgroups continue to emerge as profiling resolution and cohort sizes increase 11-13. Due to the high 
clinical relevance, the genome-wide analysis of childhood CNS tumors has become increasingly 
important 12.  
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Consequently, some of the most robustly validated new biological parameters, especially in 
medulloblastoma, high grade glioma and ependymoma, have been included into the 2016 version of 
the WHO Classification of Tumors of the Central Nervous System 3.  
For example, in the previous WHO-classification 14, the diagnosis of medulloblastoma and its 
subtypes was defined by histopathological parameters (desmoplasia, anaplasia, or large-cell 
components). In addition to histopathological features the 2016 WHO version defines 
medulloblastoma subgroups by molecular characteristics i.e. WNT-, sonic hedgehog (SHH)-, 
TP53mutated/SHH-, group 3 and group 4 3. The biological understanding and prognostic value of 
other parameters in medulloblastoma continues to emerge as profiling resolution and cohort sizes 
increase. Novel molecular subgroups, predictive of disease risk within Group 3 and Group 4 tumors, 
have recently been reported 11, alongside the discovery of biomarkers defined by specific aberrations 
(e.g. chromosome 11 loss in Group 4 medulloblastoma 15), which now require further validation prior 
to clinical use. Recent analyses of neurocognitive outcomes per biological subgroups in 
medulloblastoma showed that biological subgroups have an association with clinical, neurocognitive 
and health-related quality of life outcomes, with different rates of post-operative complications (less 
cerebellar mutism and motor deficits, less pronounced information processing speed decline, and 
better health-related quality of life in surviving SHH patients) 16,17. It has been agreed internationally 
that whenever possible, patients should be treated on a molecularly informed clinical trial. The first 
international clinical trials of risk-adapted therapies focused on the assessment of clinical, 
pathological and molecular biomarkers are now underway (NCT02066220, NCT01878617), based on 
risk stratification schemes defined in previous trial-based biological research studies, e.g. from Ellison 
et al. 18. Finally, first insights are emerging into the biology of medulloblastoma at relapse; these have 
shown that the disease evolves clonally and that genetic events, such as combined TP53 mutations 
and MYC/N amplification, are commonly acquired at relapse 19,20. Assessment of distinct molecular 
features at relapse will thus be essential for determining the treatment strategy. 
In pediatric high-grade gliomas, the molecularly defined new tumor entity, diffuse midline glioma 
(DMG IV) has been introduced, which is exclusively defined by demonstration of K27M mutations in 
the H3F3A (histone 3.3) or HIST1H3A/B/C (histone 3.1) genes. This tumor entity and its WHO grade 
are defined by demonstration of specific histone mutations besides infiltrative growth characteristics 
and midline location, rather than by the usual histological criteria of malignant tumor growth. Of 
note, H3G34R/V tumors (about 10 to 15%) were not mentioned separately despite clear age, 
location, outcome and biological differences. Furthermore, rare pediatric high grade gliomas (HGG) 
such as WHO grade III anaplastic oligodendroglioma (AO III), WHO grade III anaplastic ganglioglioma 
(AGG III), and WHO grade III anaplastic pleomorphic xanthoastrocytoma (APXA III) are also mostly 
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defined by specific molecular findings or their absence. For pediatric AO III, the usual 1p 19 q co-
deletion which defines most adult AO III according to the new WHO brain tumor classification, is 
mostly absent in their pediatric counterparts. BRAF mutations (as well as homozygous CDKN2A/B 
deletions) may characterize pediatric AGG III and APXA III. The integrated genomic, epigenomic and 
transcriptomic data across anatomical compartments of the brain is needed to define subgroups 
within pediatric high-grade glial tumors (malignant glioma and diffuse intrinsic pontine glioma) as 
well as novel therapeutic targets 21,22. 
For ependymoma, the assessment of RELA-fusion is required for diagnoses according to the 2016 
classification, while posterior fossa biological subgroups A and B (PFA and PFB 23) have not yet been 
introduced into the WHO classification. In addition, further prognostic markers have been confirmed 
retrospectively in multiple case series (1q gain, CDKN2A homozygous deletion, TNC expression, Yap1-
fusion gene) 24. The current consensus on the clinical management of intracranial ependymoma and 
its molecular variants has recently been published, and states that ependymoma is a (molecularly) 
heterogenous disease 25. However, the clinical relevance of many driver epigenetic and genetic 
alterations, either as prognostic markers or as markers predictive of therapeutic efficacy, remains to 
be prospectively validated.  
CNS primitive neuroectodermal tumors (CNS-PNET) were classified as one entity of embryonal brain 
tumors in the previous WHO-classification 14. In the meantime, it has become clear e.g. by DNA 
methylation profiling that a major part of tumors previously classified as CNS-PNETs, can be 
reclassified as other malignant CNS tumors such as high grade glioma, pleomorphic 
xanthoastrocytoma, atypical teratoid/rhabdoid tumor (AT/RT), ependymoma etc. 26. Another major 
subset can be classified as embryonal tumors with multilayered rosettes (ETMR) by LIN28 expression 
analysis and 19q13.42 amplification detection 27. New molecular entities have been described among 
the former group of presumed CNS-PNETs: CNS-neuroblastoma with FOXR2 activation (CNS NB-
FOXR2), CNS high-grade neuroepithelial tumor with MN1 alteration (CNS HGNET-MN-1) or with BCOR 
alteration (CNS-HGNET-BCOR), and CNS Ewing sarcoma family tumor with CIC alteration (CNS EFT-
CIC) 26. 
The majority of molecular profiling performed on atypical teratoid/rhabdoid tumors tissue to date 
points strongly towards the existence of multiple molecular subgroups within the disease 28. It is 
imperative to consolidate these early findings into a consensus molecular classification which may be 
applied to further tumor samples and tested against high-quality clinico-pathological data to validate 
the prognostic nature of any molecular sub-groupings.  
During the past decade the molecular background of pediatric low grade gliomas (LGG) has become 
clear, showing that LGG and glial-neuronal tumors are mainly driven by altered signaling in the RAS-
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MAPK pathway 29. In particular, pilocytic astrocytoma shows mainly BRAF tandem duplications at 
chromosome 7q34 mainly with fusion of KIAA549 and BRAF in 65% leading to loss of the regulatory 
N’-terminal region of BRAF and the formation of fusion proteins. This BRAF fusion correlates with 
improved progression-free survival (PFS) 30. Besides the fusion as biologic background tumorigenic 
BRAF activation occurs in ganglioglioma and pleomorphic xanthoastrocytoma with point mutations at 
position 600 with glutamate substitution for valine, BRAFV600E. Other oncogenetic changes in LGG 
are found in rearrangements of FGFR1, MYB and MYBL1 associated with morphologies of DNET and 
angiocentric glioma respectively 31. The malignant transformation found in about 2% of children with 
LGG has been found to be related to additional homozygous deletion of CDKN2A 32. 
The mutational landscape of CNS germ cell tumors (GCT) is becoming described 33-36 and highlighted 
the biological similarity of these tumors to their extracranial counterparts. These studies have 
identified mutational activation of KIT/RAS/ERK and AKT as well as the PI3K/MTOR pathways, 
representing potential targets for therapy. Given the limited CNS GCT tissue specimens available to 
study in North America and Europe, collection of serum/plasma and CSF may in future allow non-
invasive diagnosis using the elevation of specific microRNAs (miR-371~373 and miR-302/367) 37, 
based on findings in GCT tissues 38. In addition, these less-invasive biospecimens will allow the 
identification of specific mutations through circulating tumor DNA (ctDNA) analysis 39, which may 
inform prognosis and/or novel treatment strategies. 
Recent research revealed the frequent presence of a BRAF mutation in papillary craniopharyngioma 
CP) 40 and first case reports document excellent response rates to BRAF inhibitors in adults 41. 
However, this treatment option – potentially avoiding invasive surgery or radiation and associated 
complications – does not apply to adamantinomatous CP (aCP) in children. Despite limited availability 
of pediatric tissue specimen, promising biological research relating to aCP 42,43 has been published 
with the prospect of identifying targets for new therapies. This research is of fundamental 
importance to children affected by aCP but can only be continued if tumor specimen including cyst 
fluid are routinely sampled. 
In its 2007 and 2016 editions, the WHO classification discerns three grades of choroid plexus tumors 
(CPT): classical plexus papilloma grade I (CPP), atypical plexus papilloma grade III (APP) and plexus 
carcinoma grade III (CPC). Recently several groups have shown that DNA methylation, SNP-profiling, 
and gene expression defines clinically overlapping groups of CPTs 44. 
The accelerated understanding drove the decision for an earlier, 4th edition update of the CNS WHO 
rather than waiting longer for a 5th edition. However, there is still concern that the pace of change in 
the field creates a need to evaluate classification progress faster than is possible through standard 
WHO updates. Therefore, an initiative to evaluate and recommend proposed changes to future CNS 
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tumor classifications has been announced: cIMPACT-NOW, the Consortium to Inform Molecular and 
Practical Approaches to CNS Tumor Taxonomy. The goal of cIMPACT-NOW is to facilitate input and 
consensus review of novel diagnostically relevant data and determine how such information can be 
practically incorporated into future CNS tumor classifications 45. 
 
Access to novel therapies  
 
Importantly, the SIOPe has called for revisions to the EU Pediatric Medicine Regulation, aiming to 
increase young patients’ access to innovative therapies. This call resulted in a specific report from the 
European Commission to the European Parliament and the Council describing “The state of pediatric 
medicines in the EU - 10 years of the EU Pediatric Regulation”, which concluded that the Pediatric 
Use Marketing Authorizations (PUMA) concept has so far failed to incentivize the development of 
pediatric medicines 46. In North America, the RACE (Research to Accelerate Cures and Equity) for 
Children Act would require companies to apply PREA (Pediatric Research Equity Act) to any 
treatment with a molecular target that is relevant in adult and childhood disease. Successful 
biomaterial collection is a key prerequisite for preclinical research projects aiming to identify 
effective new drugs for children with CNS tumors, and therefore will contribute to their improved 
access to novel therapies.  
 
Tumor predisposition genes 
 
In addition to the entity-specific aspects, germline mutations in tumor predisposition genes in 
pediatric cancer are more frequent than previously thought. They have been shown in 8.6 % of 
pediatric brain tumor patients, and some of the pediatric cancers most often associated with 
germline mutations are CPT, atypical teratoid/rhabdoid tumors, medulloblastoma (TP53-mutated 
SHH MB – potential Li-Fraumeni syndrome, PTCH or SUFU-mutated SHH MB – Gorlin syndrome, APC-
mutated WNT MB – Turcot syndrome), HGG, LGG and ependymoma 47. Patients and families need to 
be referred for genetic counseling, to be informed of potential underlying predisposition syndromes. 
 
The need for tumor tissue for precision medicine 
Broadly applicable methods for the genomic analysis of childhood brain tumors including methods 
for genome-wide discovery and precision medicine have been established 12. However, broader 
availability of tumor- and constitutional DNA is required to understand the full spectrum of 
frequencies and the important clinical implications regarding targeted treatments, treatment-related 
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toxicities, secondary malignancies, and the optimal treatment and surveillance strategies for those 
patients and families. In this regard, it will be important to develop appropriate research models for 
each specific pediatric CNS tumor type and subtype to test new treatments and targeted agents. 
Currently, a number of primary cell lines and corresponding orthotopic xenograft models have been 
developed for medulloblastoma 47-50, and HGG/DIPG 51-54, but good orthotopic patient-derived 
xenograft (PDX) models for all other types of CNS tumors are scarce or lacking. Thus, while collecting 
material for tumor characterization, some tissue or CUSA (Cavitron Ultrasonic Surgical Aspirator) 
material should also be collected for the establishment of cell cultures, animal models or organoids 
55.  
Beyond current exploratory and validation research activities, biology data will also be needed for 
future diagnostic re-evaluations. Especially in long duration clinical trials, relevant improvement of 
knowledge on diagnostic groups as well as relevant host factors (cancer predisposition, genotype 
variants in treatment efficacy) can emerge between time of patient inclusion and trial data analysis. 
Also, stored research material helps to characterize rare tumors that do not fall into any of the 
currently appreciated entities.  
 
The importance of biological assessments with relevance to tumor imaging 
The radiological heterogeneity of individual tumor types is increasingly apparent with advances in 
qualitative and quantitative analysis of both conventional and advanced MR imaging methods 56,57. In 
addition to pathological classification, the emerging evidence of the biological variations, particularly 
molecular subgroups has stimulated interest in the field of imaging genomics or radiogenomics that 
focuses on the relationship between imaging phenotypes and genomics. 
Recent studies have identified correlations between IDH mutation status in gliomas and relative 
cerebral blood volume (rCBV) 58. Detection of 2-hydroxyglutarate (2-HG) on MR spectroscopy has 
been proposed as a useful biomarker for Gliomas with IDH 1 mutation 59. In the pediatric population 
MR characteristics of medulloblastoma subtypes have been described based on conventional imaging 
60 and MR spectroscopy 61. Similar studies need to be carried out in various pediatric brain tumors to 
identify imaging surrogates or biomarkers that complement their biological profile. The collection of 
biological material is central to the development of radio genomics in pediatric neurooncology. It has 
the potential to aid decision making prior to surgery, guiding biopsy and measure efficacy of 
treatment using quantitative methods.  
 
The importance of adequately sampled and stored biomaterial 
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The main advantages of the collection of biomaterials in adequate quality and quantity are the 
improved etiopathological understanding of pediatric CNS tumors, the validation and discovery of 
prognostic factors and drugable targets, the improvement of first-line and relapse treatment 
decisions for individual patients as well as within clinical trials and related research, the possibility to 
use the tissue for tumor vaccination strategies, and new insights in biology of acute toxicities and 
late-effects. In addition, frequencies of tumor predisposition syndromes and their clinical behavior 
can only be better understood by analyzing broader series of tumor- and germline material from 
patients with well-annotated clinical information about familiar history, diagnosis, treatment and 
follow-up. In consequence, bio-pathological characterization is now essential for diagnosis, risk 
assessment, therapeutic stratification and potentially specific treatment allocation in all patients with 
medulloblastoma, as well as underpinning future research studies and discoveries. Therefore, 
comprehensive bio-pathological characterization is routinely required before the start of 
postoperative treatment (e.g. radiotherapy, neoadjuvant or adjuvant chemotherapy) in individual 
patients. The most relevant arguments are listed in table 1. 
 
The need for tumor tissue for precision medicine 
 
Broadly applicable methods for the genomic analysis of childhood brain tumors including methods 
for genome-wide discovery and precision medicine have been established 12. However, broader 
availability of tumor- and constitutional DNA is required to understand the full spectrum of 
frequencies and the important clinical implications regarding targeted treatments, treatment-related 
toxicities, secondary malignancies, and the optimal treatment and surveillance strategies for those 
patients and families. In this regard, it will be important to develop appropriate research models for 
each specific pediatric CNS tumor type and subtype to test new treatments and targeted agents. 
Currently, a number of primary cell lines and corresponding orthotopic xenograft models have been 
developed for medulloblastoma 48-51, and HGG/DIPG 52-55, but good orthotopic patient-derived 
xenograft (PDX) models for all other types of CNS tumors are scarce or lacking. Thus, while collecting 
material for tumor characterization, some tissue or CUSA (Cavitron Ultrasonic Surgical Aspirator) 
material should also be collected for the establishment of cell cultures, animal models or organoids 
56.  
Beyond current exploratory and validation research activities, biology data will also be needed for 
future diagnostic re-evaluations. Especially in long duration clinical trials, relevant improvement of 
knowledge on diagnostic groups as well as relevant host factors (cancer predisposition, genotype 
variants in treatment efficacy) can emerge between time of patient inclusion and trial data analysis. 
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Also, stored research material helps to characterize rare tumors that do not fall into any of the 
currently appreciated entities.  
 
The importance of biological assessments with relevance to tumor imaging 
 
The radiological heterogeneity of individual tumor types is increasingly apparent with advances in 
qualitative and quantitative analysis of both conventional and advanced MR imaging methods 57,58. In 
addition to pathological classification, the emerging evidence of the biological variations, particularly 
molecular subgroups has stimulated interest in the field of imaging genomics or radiogenomics that 
focuses on the relationship between imaging phenotypes and genomics. 
Recent studies have identified correlations between IDH mutation status in gliomas and relative 
cerebral blood volume (rCBV) 59. Detection of 2-hydroxyglutarate (2-HG) on MR spectroscopy has 
been proposed as a useful biomarker for Gliomas with IDH 1 mutation 60. In the pediatric population 
MR characteristics of medulloblastoma subtypes have been described based on conventional imaging 
61 and MR spectroscopy 62. Similar studies need to be carried out in various pediatric brain tumors to 
identify imaging surrogates or biomarkers that complement their biological profile. The collection of 
biological material is central to the development of radio genomics in pediatric neurooncology. It has 
the potential to aid decision making prior to surgery, guiding biopsy and measure efficacy of 
treatment using quantitative methods.  
 
The current situation and shortfalls 
 
Currently, the collection of high-quality, adequately sampled and stored biomaterial is implemented 
successfully only in a minority of centers. This is mainly due to deficits in established structures, 
interdisciplinary cooperation, and funding. Professionally trained staff and required equipment is 
only available in some centers, and may also need to be professionalized at the central level of 
research consortia. Active collaboration of all involved disciplines, including neurosurgeons, 
neuropathologists, and pediatric oncologists, is not always established, and might be compromised 
due to potential conflicts of interest with other local research initiatives. In addition, the required 
personal and infrastructural burden for successful biomaterial collection is not adequately 
compensated by additional funding. 
 
Proposals for improved biomaterial collection 
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To overcome the current limitations, strong cooperative efforts of representatives from all involved 
disciplines are required. The collection and storage of required biomaterial must become a routine 
standard for all children with CNS tumors, regardless of their inclusion in clinical trials or other 
research initiatives. Moreover, it must become increasingly mandatory in future prospective 
pediatric CNS tumor trials. For their optimal collection in local institutions and within cooperative 
research groups, clear definitions of the types of biomaterials with standard operating procedures 
(SOP) must be implemented, together with thorough solutions for all associated ethical, legal and 
practical aspects.  
 
Which biomaterials need to be collected and how? 
 
To maximize the above mentioned advantages and to obtain a comprehensive biological 
understanding of tumor and host-related factors, different types of biomaterials need to be 
collected. Adequate amounts of tumor tissue, taking into account safety of the patient, should be 
collected threefold: 1/ as unfixed snap-frozen tissue, 2/ as formalin-fixed paraffin embedded 
material, and 3/ as viable native material in transport media (or viably frozen cells) for direct tumor 
cell culture or direct xenografting in animals. Blood as preferred choice or buccal swabs should be 
collected for germline analyses. In addition, constitutional DNA is required for comparison with 
genomic analyses from the corresponding tumor tissue, as tumor-specific alterations of genes, 
related signaling pathways, and drugable targets can only be identified and understood by 
comparison of tumor and germline material. A list of types of biomaterials to be collected and 
technical aspects of collection and storage is given in Table 2. 
Various technical aspects of collection and storage of biomaterials need to be carefully considered to 
obtain useful amounts of the required materials of optimal quality. This requires first of all a 
fundamental change in the pediatric neurosurgeons perception, that they play two equally important 
and pivotal roles in the process of treatment. Neurosurgeons need to appreciate, that apart from 
their primary role with regard to performing ideally a gross total tumor resection without causing any 
additional harm to the patients, there is an equally important secondary role by performing a 
threefold tissue sampling during surgery. 
The operative procedure per se should be adapted, because much more time needs to be devoted to 
collect tissue with tumor grasping forceps from different areas of the tumor, instead of mostly using 
suction or ultrasonic aspirators to take out the bulk of tumor tissue. Piecemeal sampling with the 
tumor forceps is, especially in either very soft or very hard-elastic tumors, very time- and patience 
consuming and can prolong a surgical procedure up to 30 minutes, especially if tumors are very 
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bloody. Information about the heterogeneity of tumors from MRI (diffusion-weighted sequences) or 
positron-emission-tomography may be used to specifically obtain tissue from various tumor areas. 
In addition, a more or less self-running tissue processing SOP needs to be enacted among the theater 
staff, because the sampled tissue needs to be processed in parallel to the tumor removal, which 
takes full attention of the surgeon and the scrub nurse. The pathologist might be involved at that 
time to determine the samples collected being tumor tissue. After the end of the collection period, 
samples need to be transferred by a third person from the staff to sterile vials and immediately snap 
frozen in -80ºC freezers or liquid nitrogen, either option needs to be available close to the operating 
rooms. The samples for tissue cultures need to go into appropriate vials with media for delayed 
transfer to the lab within 24h or have to be transferred directly to the lab. Only the usual pathology 
for FFPE material can stay and be processed „as always“. However, neurosurgeons need to know that 
molecular genetic array diagnostics need additional material to extract enough DNA. Thus, generous 
sampling is essential and the time needs to be invested.  
To make the tissue sampling SOP work well, theater staff needs to be informed and made 
enthusiastic for this additional work they have to cope with. There needs to be a thorough 
understanding in all personnel involved, that the tissue processing they are performing is not “just 
for research”, but has an enormous impact on the patients chances of survival, equal to the impact of 
operation and tumor removal itself. Understanding the importance of their role in this process will 
make them efficient and reliable members of the process.  
Finally the sampling effort is a team effort and, despite the fact that it is done in the neurosurgical 
theater, the neurosurgeon’s focus will properly be on the operation itself. Thus the tissue processing 
pipeline needs to be established as an interdisciplinary effort and adapted to the local conditions 
including oncology, pathology and theater staff. Since especially malignant tumors of the posterior 
fossa might undergo emergency surgery or weekend surgery, the SOP for tissue processing needs to 
be organized in a way that it will function 24/7. 
Blood, plasma and serum are important to elucidate the role of circulating tumor cells, extracellular 
vesicles, cell-free DNA, proteins and other key parameters. Cerebrospinal fluid samples can be used 
in metastatic tumors, as the access to macroscopic metastatic lesions is frequently limited and only 
possible by additional invasive procedures. Appropriate diagnostic methods for liquid biopsy may 
serve to identify future markers for minimal residual disease 63,64. As tumor tissue from metastatic 
sites can otherwise only be obtained by more invasive procedures, cerebrospinal fluid (CSF) may not 
only be used to detect microscopic tumor dissemination in cytospin samples, but may also serve to 
analyze metastatic tumor DNA, microRNA (miRNA) or proteins in the CSF-supernatant, to enhance 
knowledge about metastatic tumor spread or disease progression/evolution. 
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Importantly, biologic material should also be collected later-on during the disease course and after 
treatment. To speed up the biological understanding of tumor evolution and the appearance of 
resistance mechanisms, it is of paramount importance to collect tumor tissue at the time of relapse, 
or through autopsy. To ensure maximal biological information at tumor recurrence, re-biopsy of 
relapsed tumors should be generally recommended, with exceptions only if associated risks are 
increased in individual cases.  
In addition to the specifications about the collected biomaterial outlined above, there are important 
considerations at the ‘central’ level of research consortia or clinical trial groups, as well as at the level 
of ‘local’ institutions (figure 1). Moreover, ethical, legal and practical aspects must be considered.  
 
Ethical, legal, privacy, and practical aspects at the central level of a research consortium or clinical 
trials group 
 
Studies have shown clear support from patients and their representatives, who, once in receipt of 
adequate information, are largely in favor that biomaterials not required for diagnostic procedures 
are made available for research projects 65,66. However, important ethical, legal, privacy and practical 
aspects need to be considered in the process of collection, storage, shipment, and sharing of 
biomaterials. For example, the legal definitions for ownership of biomaterials, and guidelines for 
informed consent may vary between countries 67, and need to be considered for individual patient 
care and in the conduct of international clinical trials. Due to the advantages of accurate diagnostic 
procedures and translational research, it is increasingly accepted that the availability of biomaterials 
is defined as a mandatory inclusion criterion for patients within clinical trials (e.g. within the SIOPE-
PNET5-MB trial 68). This may not only be justified if biomaterial is a prerequisite for stratification of 
patients within a clinical trial, but also to ensure maximal scientific progress from associated 
biological research projects. The availability of biomaterials will facilitate future diagnostic and 
research evaluations of newly defined biomarkers, targets or host factors, which may impact on the 
understanding of the clinical results of the trials. The main ethical, legal, privacy, and practical 
aspects of storage, sharing, and shipment of biomaterials are listed in Table 3. 
 
Biobanking 
 
In addition, advantages of central or decentralized (virtual) biobanking need to be considered. 
Biomaterials can be stored centrally by academic or commercial tumor bank providers, with software 
systems allowing for maximal transparency about the stored materials. Alternatively, they can be 
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stored within the respective local tumor banking facilities, and may be shipped according to the 
requirements of further analyses (diagnostic analyses or collaborative research projects) in batches 
at later time points. Both central and decentral storage of biomaterials will also allow its use for big 
data analyses with bioinformatical support, and facilitate a comprehensive cataloguing of 
biomaterials for collaborative projects between research consortia. In any case, SOPs to control 
tumor samples for appropriate tissue representation must also be implemented. Storage of 
biomaterials in aliquots allows the tissue to be used for multiple research projects. Transparent 
criteria for the access of scientists from local contributing institutions and for independent 
researchers to the larger biomaterial series may positively impact the cooperation of local centers. 
Material transfer agreements, SOPs for shipment of materials, and adequate coverage of costs may 
further facilitate cooperative tumor-banking. In addition, it is important to define coupling of tumor 
material data to patient data: genomic, transcriptomic, methylomic, metabolomics data from tumor 
biopsies, as well as data from experiments on patient-derived cell cultures and xenografts, should 
ideally be stored in an international CNS tumor registry such as the recently established SIOPE DIPG 
Registry 69, together with comprehensive anonymous clinical, radiological and pathology data of 
these patients. This will allow for comprehensive Big Data analyses. In this respect, it is of high value 
to invest in gathering large numbers of retrospective clinical data (baseline characteristics, treatment 
and survival data) from multiple international groups, and to correlate these with analysis of 
(epi)genomic data from corresponding banked tumor samples.  
National and international research consortia and/or clinical trial groups must consider these aspects 
and discuss these early in the planning phase of collaborative projects, so that specific national 
requirements can be implemented in timely manner. Sustainability of data beyond projects and 
connection of data at overarching levels should be envisioned. Recent large-scale sequencing by 
International Cancer Genome Consortium and Paediatric Cancer Genome Project has further shown 
that the genetic and epigenetic repertoire of driver mutations in specific childhood malignancies 
differs from more common adult-type malignancies. To bring about much needed change, pediatric 
platforms such as ACCELERATE have been proposed by the Cancer Drug Development Forum, 
Innovative Therapies for Children with Cancer, the European Network for Cancer Research in 
Children and Adolescents and the SIOPe 70. These platforms aim to develop mechanism-of-action 
informed paediatric drug development programmes with aggregated databases of paediatric 
biological tumour drug targets, to ultimately enable prioritisation and conduct of early phase clinical 
paediatric trials more rapidly. 
 
Access to novel therapies  
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Importantly, the SIOPe has called for revisions to the EU Pediatric Medicine Regulation, aiming to 
increase young patients’ access to innovative therapies. This call resulted in a specific report from the 
European Commission to the European Parliament and the Council describing “The state of pediatric 
medicines in the EU - 10 years of the EU Pediatric Regulation”, which concluded that the Pediatric 
Use Marketing Authorizations (PUMA) concept has so far failed to incentivize the development of 
pediatric medicines 70. In North America, the RACE (Research to Accelerate Cures and Equity) for 
Children Act would require companies to apply PREA (Pediatric Research Equity Act) to any 
treatment with a molecular target that is relevant in adult and childhood disease.  
Local institutions need to implement practical solutions according to their structures 
 
It has become evident that the collection and storage of biomaterials can only be achieved 
successfully, if all relevant steps are solved in each local participating center. As personal and 
organizational structures are highly different between local participating centers, a general schema 
may not work in all centers in the same way. The above mentioned aspects rather need to be 
adapted individually by the local institutions to their structures, ideally by a dedicated local 
coordinator supported by all other involved disciplines (see table 4). Ultimately, the practical tasks 
and responsibilities need to be defined and assigned to responsible individuals. As neurosurgical 
interventions are also undertaken during the night or weekend, SOPs should be established for the 
adequate storage of tissues outside of regular day-time working hours. Specific education and 
training modules should be developed. 
 
Conclusion 
 
The availability of adequately sampled and stored biomaterial will confer multiple advantages of 
highest scientific and clinical relevance, such as validation of described and identification of new 
prognostic factors and drugable targets. This paper aims to stress on the need of biomaterial 
sampling, and includes also highly relevant practical, ethical, and privacy aspects. Improved sampling 
of biomaterial is a major prerequisite for the improvement of survival rates for children with CNS 
tumors, and to reduce treatment-related late-effects.  
In addition to increasing knowledge about the roles of conventional treatment modalities in 
biologically well-defined entities and subgroups, it must be ensured that children are not left behind 
while precision oncology offers new treatment solutions for adult cancers 71. As pediatric tumors are 
clinically and biologically highly distinct from adult cancers, these approaches must be redeveloped in 
18 
 
oncologic diseases, with informative biomaterial. Ideally, data from tumor tissues and biomaterials 
would be coupled to corresponding anonymous patient data, such as demographics, diagnostic 
features, radiology and pathology treatment and outcome data, as exemplified by the recently 
established SIOPE DIPG Registry. 
Only with widely available informative biological material, profound improvements can be achieved 
in reasonable time, both for individual patients as well as for future clinical trial groups of patients. 
Without the proposed improved biomaterial collection, optimal patient care cannot be delivered at 
the level of diagnostic assessments, applied treatment components, and after care. Likewise, the 
urgently required scientific progress in the field will be significantly delayed or impeded. 
 
In summary, tumor tissue and other biomaterials need to be collected from all children with CNS 
tumors, and will become increasingly mandatory in prospective pediatric CNS tumor trials. Strong 
cooperative efforts of representatives from all involved disciplines, in local institutions and within 
cooperative research groups, are required to efficiently implement the collection and storage of 
required biomaterial.  
 
Search strategy and selection criteria 
 
In this review, chairs and representatives of the SIOPe Brain Tumor Group (BTG) 
(https://www.siope.eu/european-research-and-standards/clinical-research-
council/siopecrc/european-clinical-study-groups/siope-brain-tumour-group/) have summarized their 
views how to efficiently improve biomaterial collection for children with CNS tumours, and why this 
is urgently required. This has been based on the profound experiences in the conduct of national and 
international multicenter clinical trials and collaborative research projects. Cited literature for this 
policy review has been primarily selected by relevance and actuality rather than being object of 
systematic literature review. SIOPe BTG is a European multidisciplinary association of healthcare 
professionals which leads in research, treatment (among which international clinical trials) and care 
of children and young people with tumors of the CNS. It is a subgroup of the European branch 
(SIOPe) (http://www.siope.eu/) of the International Society of Paediatric Oncology (SIOP) 
(http://siop-online.org/).  
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Table 1. Advantages of adequately sampled and stored biomaterials from tumor and healthy tissue 
 
Adequately sampled and stored biomaterial 
is a continuous prerequisite for validation of candidate prognostic factors, and for the discovery of 
new parameters with clinical significance 
is needed from well documented patients treated homogeneously within prospective clinical trials 
(to avoid selection bias from large retrospective series and for consideration of the prognostic 
effect of applied treatment modalities) 
is required for validation of reported targets and the identification of new drugable targets  
is the basis for current and future treatment decisions for individual patients, at clinical trials level 
and for related research directions 
allows to identify relevant biopathological mechanisms of tumor etiology, and biological drivers for 
tumor growth, and resistance to treatments (commonly across pediatric CNS tumors, and within 
specific entities and subgroups) and will contribute to improve therapeutic solutions 
increases the understanding of  biological drivers for relapse (especially if paired sets of biological 
tissues, from time of initial diagnosis and from time of relapse, are available) 
contributes to the understanding of the tumor micro-environment, other host-related factors and 
immunological aspects of tumor control 
allows to identify appropriate diagnostic methods for liquid biopsy and may serve to identify 
future markers for minimal residual disease 
facilitates identification and/or validation of associations of genetic polymorphisms with  
pharmacokinetic assessments and observed treatment-induced acute toxicities and/or late effects 
(hearing deficits, cognitive impairments, hematological toxicities etc) 
will enhance knowledge about the frequency of germline-mutations with treatment-related 
toxicities, secondary malignancies, and improve recommendations for diagnostic procedures and 
genetic counselling 
will be fundamental for the interpretation and comparability of clinical trial cohorts, including the 
evaluation of applied treatment modalities 
will help identify surrogates for specific aspects of tumor imaging or biomarkers for tumor 
subgroups that can contribute to patient management 
will allow the establishment of preclinical animal models and cell lines to test novel treatment 
modalities 
will allow possible therapeutic use of the tissue (e.g. for tumor vaccination strategies) 
will ultimately speed up the urgently required scientific progress for children with CNS-tumors as 
well as early access to new drugs in the context of appropriate clinical trials (targeting of receptors 
Table 1 unchanged
and signaling pathways, epigenetic alterations, microenvironment and immune system) 
 
Table 2. Biomaterials to be collected and proposals for collection and storage 
 
Material Amount Priority Processing Purpose Assay 
Tumor 
tissue 
Min. 1 x 1.5 cm³ or 3 x 0.5 cm³. 
Consider heterogeneity of tumor tissue. 
When stereotactic biopsy: 2 x 4 needle 
biopsies are recommended.  
1 Formalin-fixed, paraffin embedded of viable 
tissue sampled early during dissection to obtain 
viable tumor tissue (avoid crushing) 
Diagnostics IHC/DNA methylation array 
Touch imprint preparation or 1 x 0.5 cm³ 1 Within 20 min from resection snap frozen at -
80°C 
Diagnostics FISH, DNA/RNA sequencing 
1 x 0.5 cm³ 2 Within 20 min from resection snap frozen in N2 
or at -80°C 
Research DNA/RNA sequencing 
1 x 0.5 cm³ 3 Culture medium (living cells) Research Cell culture/PDX models 
1 x 0.5 cm³ 4 Paraformaldehyde Research Imaging 
> 1.5 cm³
1
 1 Sterile, without additives, within 20 min from 
resection snap frozen at -80°C 
Immunotherapy  
CUSA All available material 2 Culture medium Research Cell culture/PDX models 
Blood 5 ml EDTA
2
 1 WBC Diagnostics DNA 
5 ml EDTA 3 Platelets 
72
 Research RNA 
5 ml EDTA 2 Plasma 
73,74
 Research DNA/RNA/extracellular vesicles
4
 
5 ml serum 2 Serum 
75
 Research DNA/RNA/extracellular vesicles
4
 
CSF
3
 All available material 1  Diagnostics Cytology 
All other available material 2  Research DNA/RNA/extracellular vesicles
4
 
Normal 
CNS tissue 
Obtain during placement of a VP-shunt or 
subcutaneous intraventricular device or 
performance of third ventriculoscopy 
3 Equal to tumor tissue: FFPE and snap frozen Research IHC/DNA methylation array, 
FISH, DNA/RNA sequencing 
Saliva, 
urine 
1 - 5 ml 4  Research DNA, pharmacokinetics, 
extracellular vesicles analyses
4
 
 
 
                                                          
1
 In case an operation is performed in part with the goal to obtain tumor tissue for preparing dendritic cell vaccines. 
2
 Constitutional DNA can eventually be taken via buccal swab. 
3
 CSF can be collected during operation. For some treatment schedules, CSF can be taken 14 days after operation.  
4 
For analyses of extracellular vesicles, material should be processed within one hour according to specific procedures (http://evtrack.org).  
Table 2 unchanged
Table 3. Ethical, legal, privacy, and practical aspects of storage, sharing, and shipment of 
biomaterials at the central level of a research consortium or clinical trials group 
 
Age-appropriate information sheets for patients and their legal representatives must explain the 
purpose of the planned research, recipients of material and use of anonymized or pseudonymized 
clinical data, followed by clear forms for informed consent 
Ensure that coupling of tumor material data to patient data including treatment and imaging is 
possible, allowing also for comprehensive ‘Big Data’ analyses 
Ethical approval and permissions from international and/or national and/or local authorities must 
be obtained 
To gain and provide insight in the adherence and availability of biomaterials and to identify 
potential for further improvements, consider a monitoring system for biomaterials and for 
accessory informed consents per local hospital 
Consider ownership issue for biological tissue and related clinical data, which may be different 
between countries 
Consider advantages of central versus decentralized (virtual) tumor-banking, and procedures to 
check for appropriate tissue representation for interpretable biological results 
Consider if the availability of biomaterial should be defined as a mandatory inclusion criterion for 
patients within clinical trials 
In the context of clinical trials, responsibilities of trial coordinators and local centers should be 
defined and adapted to applicable laws and regulations. 
Adequate coverage of the local costs and shipment of biomaterials by research grants will 
facilitate the compliance of local institutions 
Integrated, reusable tumor box devices may facilitate shipment of frozen and unfrozen materials  
To optimize the availability for both local and central research projects, the respective 
biomaterials should be stored in reasonable aliquots 
Practical aspects of exchange and use of biomaterials should be defined by material transfer 
agreements between research institutions within the applicable laws and regulations 
Local researchers should be able to apply for centrally stored material following transparent rules 
for evaluation of such applications, thus having benefit from their participation wherever 
appropriate 
 
Table 3 unchanged
Table 4. Aspects for standard operation procedures to be considered in local institutions 
 
Staff from all involved disciplines (neurosurgeons and operation room staff, (neuro)pathologists, 
pediatric oncologists, research nurses, etc.) must know about the importance of the availability of 
adequate biomaterials, and define the practical steps of collection, storage, and shipment of samples 
according to local structures. These steps include: 
Information and consent from patients and their legal representatives: pre-operative oral in case 
of emergency, later written consent; biobanking, research/trial documents 
Amount and types of tissue, blood, and other biomaterials 
Neurosurgical considerations (frozen section, debulking, cusa, infiltration zone, healthy material, 
CSF). Freezing and fixation of maximal amounts of material. As neurosurgical interventions are also 
undertaken during the night or weekend, SOPs should be established for the adequate storage of 
tissues outside of regular day-time working hours. 
Histopathological diagnosis, reference assessments 
MRI sending via digital route or anonymized and coded CDrom 
Adequate short term storage of tumor tissue and other materials like blood, mucosa, saliva, urine 
(labelling of samples, eventually -80° freeze in operation room in due time, labelling of samples) 
Transfer to long-term storage, or shipment of samples according to SOP 
Trial-specific requirements (e.g. touch imprint preparation for FISH) 
Supply for cell culture  
File for documentation of collected materials per study 
Confirmation of received materials at research institute 
Procedure for prioritization of pathology in case of sparse material 
 
Table 4 revised
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To  
The Editorial board 
The Lancet Oncology 
 
  Hamburg, May 8, 2018 
 
Resubmission Policy review Manuscript THELANCETONCOLOGY-D18-00435R1 
 
Dear Alexandra Sklan, dear editors,  
 
Thank you for your feedback to our revised version of our policy review  
 
“Biological material collection to advance translational research and treatment of children with CNS tu-
mors: A position paper and practical considerations from the SIOP-Europe Brain Tumor Group”. 
 
The manuscript has been revised according to the referee comments as follows: 
 
1. On page 5 the title "Classification and clinical relevance" would be improved by adding "Tumour 
classification and clinical relevance". 
Reply: This has been added to the title.  
 
2. The paragraphs "The need of tumor tissue for precision medicine" and "The importance of biologi-
cal assessments with relevance to tumor imaging", should be subheadings within the paragraph "The 
importance of adequately sampled and stored biomaterial"  
Reply: Both parts have been placed with subheadings into the indicated paragraph as suggested (pag-
es 11 and 12).  
 
3. I agree with reviewer 2 (minor comment 2) that the relevance of the paragraph "Access to novel 
therapies" on p15 is not clear in terms of its relation to biomaterial collection. Its relevance should be 
explained and incorporated into the paragraph "The importance of biological assessments in pediatric 
CNS tumors" or deleted. 
Reply: The relevance of the paragraph has been explained by adding “Successful biomaterial collection 
is a key prerequisite for preclinical research projects aiming to identify effective new drugs for children 
with CNS tumors, and will contribute to their improved access to novel therapies” at the end of this 
paragraph, and the paragraph has been incorporated as suggested (page 9).  
 
4. On p 15 in the sentence "To bring about much needed change, pediatric platforms such as ACCEL-
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Director of the Department of Paedi-
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Chair HIT-MED trial group 
www.uke.de/hit 
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ERATE have been proposed by the Cancer Drug Development Forum, Innovative Therapies for Chil-
dren with Cancer, the European Network for Cancer Research in Children and Adolescents and the 
SIOPe" it should be explained which changes can be achieved by ACCELERATE. 
Reply: The changes which can be achieved have been explained by adding the sentence “These plat-
forms aim to develop mechanism-of-action informed paediatric drug development programmes with 
aggregated databases of paediatric biological tumour drug targets, to ultimately enable prioritisation 
and conduct of early phase clinical paediatric trials more rapidly.” to the paragraph (page 16).  
Although this also refers to access to new drugs, we suggest to keep this part in the biobanking sec-
tion, as our argument arises in this context from the improved availability of biomaterials.  
 
5. On page 16 the sentence "As neurosurgical interventions are also undertaken during the night or 
weekend, SOPs should be established for the adequate storage of tissues outside of regular day-time 
working hours. Specific education and training modules should be developed."  is redundant within 
the text as it has been discussed already extensively on p 12/13, but should be added to table 4. 
Reply: As suggested, we have deleted this sentence from the text (page 17) and added it to table 4.  
As some paragraphs of the manuscript have been incorporated into other sections (see above), we 
have revised the order of the literature citations accordingly. All elements of the paper and all relevant 
information has been provided. 
 
We are convinced that the manuscript has been further improved by the changes made in response to 
the reviewer’s comments. Therefore, we hope that our manuscript will be accepted for publication in 
The Lancet Oncology.  
 
With kind regards,  
 
Prof. Dr. Stefan Rutkowski, corresponding author,  
Chair of the SIOP-Europe Brain Tumor Group 
